Q-omics provides the consensus-scored MACROD2 profile across patient tissues and cancer cell-line models. MACROD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MACROD2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, MACROD2 protein abundance shows 24,081 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, LUAD, and GBM as cancer lineages where MACROD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MACROD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MACROD2 survival associations across molecular data types. MACROD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MACROD2 RNA expression–survival associations across cancer types. High MACROD2 expression shows unfavorable associations in LUSC, DLBC and UCEC, but favorable associations in HNSC, UCS and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MACROD2 RNA expression.
This table summarizes MACROD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MACROD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MACROD2 shows lower tumor expression in LUAD, KICH, LUSC, KIRC and UCEC and higher tumor expression in THCA. The LUAD box plot shows higher MACROD2 RNA expression in normal versus tumor tissue (log2 FC = −2.184, t-test p < 0.001).
This table shows molecular features associated with MACROD2 in patient tissues and cancer cell lines. In patient samples, MACROD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MACROD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
